Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.

Current drug targets

Volumn 14, Issue 12, 2013, Pages 1444-1452

  Jovani, Manol ^a   Fiorino, Gionata ^b   Danese, Silvio ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; INTERLEUKIN 13; LEBRIKIZUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-13; SIGNAL TRANSDUCTION;

EID: 84901383078     PISSN: None     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990170     Document Type: Review

References (0)